2/4
08:29 am
acrs
Aclaris Therapeutics to Participate in Two February Healthcare Conferences [Yahoo! Finance]
Low
Report
Aclaris Therapeutics to Participate in Two February Healthcare Conferences [Yahoo! Finance]
2/4
07:00 am
acrs
Aclaris Therapeutics to Participate in Two February Healthcare Conferences
Low
Report
Aclaris Therapeutics to Participate in Two February Healthcare Conferences
2/3
07:12 am
acrs
Aclaris Therapeutics (NASDAQ:ACRS) was upgraded by analysts at Craig Hallum to a "strong-buy" rating.
Low
Report
Aclaris Therapeutics (NASDAQ:ACRS) was upgraded by analysts at Craig Hallum to a "strong-buy" rating.
2/3
04:42 am
acrs
Biosion Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial of BSI-082, a Next-Generation Anti-SIRPa Monoclonal Antibody for Advanced Solid Tumors [Yahoo! Finance]
Low
Report
Biosion Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial of BSI-082, a Next-Generation Anti-SIRPa Monoclonal Antibody for Advanced Solid Tumors [Yahoo! Finance]
1/30
08:14 am
acrs
Aclaris Therapeutics (NASDAQ:ACRS) is now covered by analysts at Craig Hallum. They set a "buy" rating on the stock.
Low
Report
Aclaris Therapeutics (NASDAQ:ACRS) is now covered by analysts at Craig Hallum. They set a "buy" rating on the stock.
1/28
08:41 am
acrs
Aclaris Therapeutics (NASDAQ:ACRS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Medium
Report
Aclaris Therapeutics (NASDAQ:ACRS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
1/27
07:07 am
acrs
Aclaris Therapeutics' Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA) [Yahoo! Finance]
Low
Report
Aclaris Therapeutics' Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA) [Yahoo! Finance]
1/27
06:55 am
acrs
Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)
Low
Report
Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)
1/21
08:00 am
acrs
Aclaris Therapeutics (NASDAQ:ACRS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Medium
Report
Aclaris Therapeutics (NASDAQ:ACRS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
1/13
08:01 am
acrs
Aclaris Therapeutics initiates Phase 1b proof-of-concept trial of ATI-052 [Yahoo! Finance]
Low
Report
Aclaris Therapeutics initiates Phase 1b proof-of-concept trial of ATI-052 [Yahoo! Finance]
1/12
06:55 am
acrs
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052
Low
Report
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052
1/6
06:59 am
acrs
Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Ra Bispecific Antibody ATI-052 Supporting Expedited Clinical Development
Low
Report
Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Ra Bispecific Antibody ATI-052 Supporting Expedited Clinical Development
12/30
04:09 pm
acrs
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/23
04:09 pm
acrs
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/19
07:04 pm
acrs
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI) [Yahoo! Finance]
Low
Report
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI) [Yahoo! Finance]
12/19
04:01 pm
acrs
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)
Low
Report
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)
11/25
08:14 am
acrs
Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
Low
Report
Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
11/25
08:00 am
acrs
Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
Low
Report
Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
11/12
01:23 pm
acrs
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Neutral
Report
Aclaris Therapeutics (NASDAQ:ACRS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.